The use of immunosuppression in autoimmune hepatitis: A current literature review

by Angela Cropley, Martin Weltman
Published 2017-03-01

NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial

by Marlyn J. Mayo, Alan J. Wigg, Barbara A. Leggett, Hays Arnold, Alexander J. Thompson, Martin Weltman, Elizabeth J. Carey, Andrew J. Muir, Lei Ling, Stephen J. Rossi, Alex M. DePaoli
Published 2018-09-01

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial

by Jason Grebely, Phillip Read, Evan B. Cunningham, Martin Weltman, Gail V. Matthews, Adrian Dunlop, Mark Montebello, Marianne Martinello, Rosie Gilliver, Philippa Marks, Tanya L. Applegate, Gregory J. Dore, the DARLO‐C Study Group
Published 2020-06-01

Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma

by Jason Behary, Nadia Amorim, Xiao-Tao Jiang, Anita Raposo, Lan Gong, Emily McGovern, Ragy Ibrahim, Francis Chu, Carlie Stephens, Hazem Jebeili, Vincenzo Fragomeli, Yen Chin Koay, Miriam Jackson, John O’Sullivan, Martin Weltman, Geoffrey McCaughan, Emad El-Omar, Amany Zekry
Published 2021-01-01

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

by Evan B. Cunningham, Behzad Hajarizadeh, Olav Dalgard, Janaki Amin, Margaret Hellard, Graham R Foster, Philip Bruggmann, Brian Conway, Markus Backmund, Geert Robaeys, Tracy Swan, Philippa S. Marks, Sophie Quiene, Tanya L Applegate, Martin Weltman, David Shaw, Adrian Dunlop, Julie Bruneau, Håvard Midgard, Stefan Bourgeois, Maria Christine Thurnheer, Gregory J Dore, Jason Grebely, on behalf of the ACTIVATE Study Group
Published 2017-06-01

Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study

by Haiyan Ma, Tien Huey Lim, Apinya Leerapun, Martin Weltman, Jidong Jia, Young-suk Lim, Pisit Tangkijvanich, Wattana Sukeepaisarnjaroen, Yun Ji, Nina Le Bert, Dong Li, Yao Zhang, Robert Hamatake, Nicole Tan, Chunming Li, Simone I. Strasser, Huiguo Ding, Jung-Hwan Yoon, Nigel H. Stace, Tanvir Ahmed, Dave E. Anderson, Li Yan, Antonio Bertoletti, Qing Zhu, Man-Fung Yuen
Published 2021-12-01

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C

by Khaled Thabet, Anastasia Asimakopoulos, Maryam Shojaei, Manuel Romero-Gomez, Alessandra Mangia, William L. Irving, Thomas Berg, Gregory J. Dore, Henning Grønbæk, David Sheridan, Maria Lorena Abate, Elisabetta Bugianesi, Martin Weltman, Lindsay Mollison, Wendy Cheng, Stephen Riordan, Janett Fischer, Ulrich Spengler, Jacob Nattermann, Ahmed Wahid, Angela Rojas, Rose White, Mark W. Douglas, Duncan McLeod, Elizabeth Powell, Christopher Liddle, David van der Poorten, Jacob George, Mohammed Eslam, International Liver Disease Genetics Consortium
Published 2016-09-01

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.

by Vijayaprakash Suppiah, Silvana Gaudieri, Nicola J Armstrong, Kate S O'Connor, Thomas Berg, Martin Weltman, Maria Lorena Abate, Ulrich Spengler, Margaret Bassendine, Gregory J Dore, William L Irving, Elizabeth Powell, Margaret Hellard, Stephen Riordan, Gail Matthews, David Sheridan, Jacob Nattermann, Antonina Smedile, Tobias Müller, Emma Hammond, David Dunn, Francesco Negro, Pierre-Yves Bochud, Simon Mallal, Golo Ahlenstiel, Graeme J Stewart, Jacob George, David R Booth, International Hepatitis C Genetics Consortium (IHCGC)
Published 2011-09-01